Results 141 to 150 of about 25,216 (236)

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, Volume 116, Issue 4, Page 357-367, April 2026.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy. [PDF]

Antib Ther
Chen D, Wu Z, Zhao X, Bhatt RS, Yang Y, Zhu W, Tang H, Wang K, Guo C, Liu D, Yang C, Guo H, Bai X, Zhang R, Li S, Tian W.   +15 more
europepmc   +1 more source

Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches

European Journal of Haematology, Volume 116, Issue 4, Page 368-379, April 2026.
ABSTRACT Follicular lymphoma (FL), traditionally considered an indolent yet incurable malignancy, is experiencing a substantial evolution in its therapeutic landscape with the emergence of chemo‐free treatment strategies. These novel approaches challenge conventional chemotherapy‐based paradigms and offer promising alternatives for both newly diagnosed
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. [PDF]

Blood Adv
Locke M, Albiez J, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T.   +8 more
europepmc   +1 more source

TOPK Inhibition Promotes Anti‐Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This study identifies TOPK as a dual‐function target in gastric cancer: it drives tumor cell proliferation and migration, and under IFN‐γ stimulation, phosphorylates eIF4F complex component eIF4A1 to enhance STAT1 mRNA translation, thereby promoting PD‐L1/IDO1‐mediated tumor immunometabolic evasion.
Junbing Chen, Longtao Huangfu, Gangjian Wang, Xueying Wang, Huanbo Zhu, Qian Yao, Cong Chen, Xiaohuan Tang, Ting Guo, Biao Fan, Xingyang Liu, Qingda Li, Zining Liu, Ying Hu, Tianze Sun, Jiafu Ji, Xiaofang Xing   +16 more
wiley   +1 more source

Exceptionally broad HIV-1 neutralization via bispecific antibody-mediated prepositioning. [PDF]

Proc Natl Acad Sci U S A
Kim S, Travisano KA, Wilder B, Palomares M, Cao Z, Seaman MS, Kim PS.   +6 more
europepmc   +1 more source

Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang   +8 more
wiley   +1 more source

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. [PDF]

Cell Oncol (Dordr)
Wang Y, Guo H, Han R, Wu Y, He T, Diao M, Xiong A, Zhou F, Cheng L, Zhao C, Li X, Zhou C.   +11 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Bispecific Antibody MDX447 [PDF]

, 2020
openaire   +1 more source